Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are also popular [9,10,11], but they are also associated with serious AEs like gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis [12]. This evidence concerns the gene GLP1R and nephrolithiasis.